Trial Demonstrates Promise for Tetanus-Diphtheria Vaccine Stable Without Refrigeration

A world-first Phase I trial of SPVX02, a tetanus-diphtheria vaccine, demonstrated promising results, showing it was well tolerated without serious adverse events. The reformulated vaccine can be stored at temperatures up to 30°C for at least two years. This innovation could significantly enhance global access to crucial treatments by reducing refrigeration dependency, minimizing waste and environmental impact.